Connection

Richard Silver to Middle Aged

This is a "connection" page, showing publications Richard Silver has written about Middle Aged.
Connection Strength

0.787
  1. PACK syndrome: A case series and review. Am J Med Sci. 2023 04; 365(4):321-328.
    View in: PubMed
    Score: 0.060
  2. Voriconazole-associated periostitis presenting as hypertrophic osteoarthropathy following lung transplantation report of two cases and review of the literature. Semin Arthritis Rheum. 2019 10; 49(2):319-323.
    View in: PubMed
    Score: 0.047
  3. Relationship of main pulmonary artery diameter to pulmonary arterial pressure in scleroderma patients with and without interstitial fibrosis. J Comput Assist Tomogr. 2014 Mar-Apr; 38(2):163-8.
    View in: PubMed
    Score: 0.033
  4. Factors associated with oral hygiene practices among adults with systemic sclerosis. Int J Dent Hyg. 2014 Aug; 12(3):180-6.
    View in: PubMed
    Score: 0.032
  5. Factors associated with gingival inflammation among adults with systemic sclerosis. Int J Dent Hyg. 2014 Feb; 12(1):55-61.
    View in: PubMed
    Score: 0.031
  6. Effect of orofacial exercises on oral aperture in adults with systemic sclerosis. Disabil Rehabil. 2012; 34(1):84-9.
    View in: PubMed
    Score: 0.028
  7. Effect of a multi-faceted intervention on gingival health among adults with systemic sclerosis. Clin Exp Rheumatol. 2011 Mar-Apr; 29(2 Suppl 65):S26-32.
    View in: PubMed
    Score: 0.027
  8. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol. 2006 Feb; 33(2):263-8.
    View in: PubMed
    Score: 0.019
  9. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis. 2005 Sep; 64(9):1387.
    View in: PubMed
    Score: 0.018
  10. Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol. 2005 Jan; 32(1):51-7.
    View in: PubMed
    Score: 0.017
  11. Patterns of hospital admissions and emergency room visits among patients with scleroderma in South Carolina, USA. J Rheumatol. 2003 Jun; 30(6):1238-43.
    View in: PubMed
    Score: 0.015
  12. Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis. J Rheumatol. 2001 Sep; 28(9):2031-7.
    View in: PubMed
    Score: 0.014
  13. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest. 2000 Oct; 118(4):1077-82.
    View in: PubMed
    Score: 0.013
  14. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis. 2020 05; 79(5):618-625.
    View in: PubMed
    Score: 0.013
  15. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol. 2019 12; 71(12):2059-2067.
    View in: PubMed
    Score: 0.012
  16. Anti-beta2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome. Am J Obstet Gynecol. 1999 Sep; 181(3):642-8.
    View in: PubMed
    Score: 0.012
  17. Randomized Controlled Trial to Evaluate an Internet-Based Self-Management Program in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2019 03; 71(3):435-447.
    View in: PubMed
    Score: 0.011
  18. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 02; 46(2):176-183.
    View in: PubMed
    Score: 0.011
  19. Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. Arthritis Rheumatol. 2018 10; 70(10):1654-1660.
    View in: PubMed
    Score: 0.011
  20. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018 01 04; 378(1):35-47.
    View in: PubMed
    Score: 0.011
  21. Symptomatic spinal calcinosis in systemic sclerosis (scleroderma). Arthritis Rheum. 1997 Oct; 40(10):1892-5.
    View in: PubMed
    Score: 0.010
  22. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2017 May; 14(5):682-689.
    View in: PubMed
    Score: 0.010
  23. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 1997 Apr; 40(4):743-51.
    View in: PubMed
    Score: 0.010
  24. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):106-113.
    View in: PubMed
    Score: 0.010
  25. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719.
    View in: PubMed
    Score: 0.010
  26. Systemic Sclerosis and Perceptions of Quality in Primary Care. Am J Med Sci. 2016 05; 351(5):447-51.
    View in: PubMed
    Score: 0.009
  27. Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Res Ther. 2016 Jan 20; 18:20.
    View in: PubMed
    Score: 0.009
  28. Eosinophilia-myalgia syndrome: a long-term follow-up study. South Med J. 1995 Sep; 88(9):953-8.
    View in: PubMed
    Score: 0.009
  29. Electron probe microanalysis of silicon and the role of the macrophage in proximal (capsule) and distant sites in augmentation mammaplasty patients. Plast Reconstr Surg. 1995 Mar; 95(3):513-9.
    View in: PubMed
    Score: 0.009
  30. Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum. 2015 Jun; 44(6):680-6.
    View in: PubMed
    Score: 0.009
  31. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014 Mar; 66(3):489-95.
    View in: PubMed
    Score: 0.008
  32. Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative. Clin Exp Rheumatol. 2014 Nov-Dec; 32(6 Suppl 86):S-21-7.
    View in: PubMed
    Score: 0.008
  33. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov; 72(11):1747-55.
    View in: PubMed
    Score: 0.008
  34. Failure of the circulatory system limits exercise performance in patients with systemic sclerosis. Am J Med. 1993 Oct; 95(4):413-8.
    View in: PubMed
    Score: 0.008
  35. Differential regulation of cell functions by CSD peptide subdomains. Respir Res. 2013 Sep 08; 14:90.
    View in: PubMed
    Score: 0.008
  36. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993 May; 20(5):838-44.
    View in: PubMed
    Score: 0.008
  37. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant. 2013; 22(12):2267-77.
    View in: PubMed
    Score: 0.008
  38. Demonstration of silicon in sites of connective-tissue disease in patients with silicone-gel breast implants. Arch Dermatol. 1993 Jan; 129(1):63-8.
    View in: PubMed
    Score: 0.008
  39. Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of patients with scleroderma. J Rheumatol. 1992 Nov; 19(11):1716-23.
    View in: PubMed
    Score: 0.007
  40. Tryptophan metabolism via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome. Arthritis Rheum. 1992 Sep; 35(9):1097-105.
    View in: PubMed
    Score: 0.007
  41. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci. 2011 Nov; 342(5):352-5.
    View in: PubMed
    Score: 0.007
  42. High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991 Oct; 18(10):1520-8.
    View in: PubMed
    Score: 0.007
  43. Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. J Rheumatol. 2011 Aug; 38(8):1622-30.
    View in: PubMed
    Score: 0.007
  44. Lymphokine activated killer (LAK) cell activity in the peripheral blood lymphocytes of systemic sclerosis (SSc) patients. Clin Exp Rheumatol. 1990 Sep-Oct; 8(5):481-6.
    View in: PubMed
    Score: 0.006
  45. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010 Aug; 62(8):2467-75.
    View in: PubMed
    Score: 0.006
  46. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 2010 Jul; 37(7):1488-501.
    View in: PubMed
    Score: 0.006
  47. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1990 May; 88(5):470-6.
    View in: PubMed
    Score: 0.006
  48. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis. 2010 Jun; 69(6):1220-6.
    View in: PubMed
    Score: 0.006
  49. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med. 1990 Mar 29; 322(13):874-81.
    View in: PubMed
    Score: 0.006
  50. Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis. Am J Med. 1989 Nov; 87(5):525-7.
    View in: PubMed
    Score: 0.006
  51. Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma. Arthritis Rheum. 1989 May; 32(5):577-83.
    View in: PubMed
    Score: 0.006
  52. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009 Apr; 60(4):1102-11.
    View in: PubMed
    Score: 0.006
  53. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009 Apr; 36(4):773-80.
    View in: PubMed
    Score: 0.006
  54. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol. 2009 Feb; 36(2):330-6.
    View in: PubMed
    Score: 0.006
  55. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008 Jan 01; 177(1):91-8.
    View in: PubMed
    Score: 0.005
  56. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):1026-34.
    View in: PubMed
    Score: 0.005
  57. Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol. 2007 Jun; 34(6):1277-82.
    View in: PubMed
    Score: 0.005
  58. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007 Dec; 66(12):1641-7.
    View in: PubMed
    Score: 0.005
  59. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007 May; 56(5):1676-84.
    View in: PubMed
    Score: 0.005
  60. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22; 354(25):2655-66.
    View in: PubMed
    Score: 0.005
  61. Interstitial lung disease in scleroderma. Immune complexes in sera and bronchoalveolar lavage fluid. Arthritis Rheum. 1986 Apr; 29(4):525-31.
    View in: PubMed
    Score: 0.005
  62. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol. 2005 Oct; 32(10):1888-92.
    View in: PubMed
    Score: 0.005
  63. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol. 2005 May; 32(5):832-40.
    View in: PubMed
    Score: 0.004
  64. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum. 2005 Feb; 52(2):592-600.
    View in: PubMed
    Score: 0.004
  65. Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. Arthritis Rheum. 1984 Nov; 27(11):1254-62.
    View in: PubMed
    Score: 0.004
  66. Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin Exp Rheumatol. 2004 Nov-Dec; 22(6):733-42.
    View in: PubMed
    Score: 0.004
  67. Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol. 2005 Jan; 288(1):L190-201.
    View in: PubMed
    Score: 0.004
  68. Wegener's granulomatosis in patients with rheumatoid arthritis. J Rheumatol. 2003 Sep; 30(9):2064-9.
    View in: PubMed
    Score: 0.004
  69. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol. 2003 Aug; 163(2):571-81.
    View in: PubMed
    Score: 0.004
  70. Is occupational organic solvent exposure a risk factor for scleroderma? Arthritis Rheum. 1998 Jun; 41(6):1111-8.
    View in: PubMed
    Score: 0.003
  71. Increased activity of the alpha 1(I) procollagen promoter in skin fibroblasts from patients with chronic eosinophilia-myalgia syndrome. Int J Biochem Cell Biol. 1997 Jan; 29(1):135-41.
    View in: PubMed
    Score: 0.002
  72. The eosinophilia-myalgia syndrome: status of 205 patients and results of treatment 2 years after onset. Ann Intern Med. 1995 Jun 01; 122(11):851-5.
    View in: PubMed
    Score: 0.002
  73. Fasciitis (not scleroderma) following prolonged exposure to an organic solvent (trichloroethylene). J Rheumatol. 1994 Aug; 21(8):1567-70.
    View in: PubMed
    Score: 0.002
  74. Chest CT in patients with scleroderma: prevalence of asymptomatic esophageal dilatation and mediastinal lymphadenopathy. AJR Am J Roentgenol. 1993 Aug; 161(2):269-72.
    View in: PubMed
    Score: 0.002
  75. Scleroderma following augmentation mammoplasty. Report of a case and review of the literature. Arch Dermatol. 1990 Sep; 126(9):1198-202.
    View in: PubMed
    Score: 0.002
  76. Familial clustering of scleroderma spectrum disease. Am J Med. 1988 Jun; 84(6):1023-32.
    View in: PubMed
    Score: 0.001
  77. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol. 1988 Jan-Mar; 6(1):7-12.
    View in: PubMed
    Score: 0.001
  78. Dipyridamole decreases platelet-derived growth factor levels in human serum. Arteriosclerosis. 1987 Mar-Apr; 7(2):152-8.
    View in: PubMed
    Score: 0.001
  79. Anticentromere antibody and immunoglobulin allotypes in scleroderma. Arch Dermatol. 1985 Mar; 121(3):339-44.
    View in: PubMed
    Score: 0.001
  80. Fibronectin distribution in nailfold biopsies of scleroderma (systemic sclerosis) patients. Acta Derm Venereol. 1985; 65(3):185-9.
    View in: PubMed
    Score: 0.001
  81. Epidermal nuclear immunofluorescence: serological correlations supporting an in vivo reaction. Br J Dermatol. 1985 Jan; 112(1):15-22.
    View in: PubMed
    Score: 0.001
  82. Immunofluorescence in skin specimens from three different biopsy sites in patients with scleroderma. Clin Exp Rheumatol. 1985 Jan-Mar; 3(1):11-6.
    View in: PubMed
    Score: 0.001
  83. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. Am J Med. 1984 Nov; 77(5):812-22.
    View in: PubMed
    Score: 0.001
  84. Immune complexes and antinuclear, antinucleolar, and anticentromere antibodies in scleroderma. J Am Acad Dermatol. 1984 Sep; 11(3):461-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.